Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Some COVID-19 Molecular Diagnostics Can Skip Forward To Market For Pooled Screening

Executive Summary

The US FDA says as long as the EUA-authorized tests provide a notification with validation data and procedural information, they can be used for pooled serial screening before additional review.

You may also be interested in...



FDA Takes Steps To Help Serial Testing Efforts, Track Asymptomatic COVID-19 Cases

The agency published a supplemental template for molecular and antigen COVID-19 EUA sponsors whose product can be used for serial testing, and a fact sheet that screening program organizers can use to pick the right test.

Quest’s First Pooled Sample COVID-19 Diagnostic Test Could Save Time, Resources: FDA

US regulators gave the thumbs-up to the first COVID-19 test that pools patient samples to determine if any one of the individuals in the pool may be infected. Despite concerns such tests may be diluted and make it harder to detect the SARS-CoV-2 virus, the FDA says validation data shows it works.

Device Week, 7 May 2021 – New MDUFA, Old Disagreements

In this week’s podcast, senior reporter Ferdous Al-Faruque gives an early look at how user fee negotiations between the US FDA and industry groups for MDUFA V are unfolding. As in the past, the parties are at odds over how much industry should pay, and what the FDA is using the money for.

Topics

UsernamePublicRestriction

Register

MT143815

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel